PENDING CLAIMS

19. (Twice amended) A method for inducing or enhancing, in a non-human subject, the production of antibodies reactive with UTAA comprising administering an effective amount of the antigen composition of claim 62 to said non-human subject.

62. (Amended) An antigen composition comprising a substantially purified [tumor antigen, wherein the tumor antigen is identified as comprising] Urinary Tumor Associated Antigen (UTAA) 90 to 100 kD subunit which[, after reduction by ß-mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis, exhibits a molecular weight of about 90 to 100 kD, and wherein said subunit] contains glycosidase-sensitivecarbohydrates, is heat stable at 100°C, and has an isoelectric point of about 6.1.

63. (Amended) The antigen composition according to claim 62, wherein said UTAA subunit is purified at least about 100-fold over UTAA found in urine.

64. (Amended) The antigen composition according to claim 62, wherein said UTAA subunit is present as at least about 0.6% of total protein in said composition.

65. (Amended) The method of claim 19, wherein said method comprises enhancing in a subject the production of antibodies reactive with said UTAA subunit.

66. (Amended) The composition of claim 63, wherein said UTAA subunit is purified 105-fold over UTAA found in urine.

69. (Amended) The composition of claim 62, wherein said UTAA subunit is about 95% free of immunoglobulin.

70. (Amended) The composition of claim 62, wherein said UTAA subunit is about 99.5% free of immunoglobulin.

72. The method of claim 65, wherein the observed enhancement of antibody production is about 2- to 5-fold.

73. (Amended) A pharmaceutical composition comprising (i) an antigen composition comprising a substantially purified [tumor antigen, wherein the tumor antigen is identified as comprising] Urinary Tumor Associated Antigen (UTAA) 90 to 100 kD subunit which[, after reduction by β-mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis, exhibits a molecular weight of about 90 to 100 kD] contains glycosidase-sensitivecarbohydrates, is heat stable at 100°C, and has an isoelectric point of about 6.1 and (ii) a pharmaceutical buffer.

74. The pharmaceutical composition of claim 73, wherein said antigen composition is present as at least about 0.63 µg/ml of buffer.

75. The pharmaceutical composition of claim 74, wherein said antigen composition is present as at least about 1.4 μg/ml of buffer.

76. The pharmaceutical composition of claim 75, wherein said antigen composition is present as at least about 36 μg/ml of buffer.

77. The pharmaceutical composition of claim 76, wherein said antigen composition is present as at least about 40 μg/ml of buffer.

78. The pharmaceutical composition of claim 77, wherein said antigen composition is present as at least about 100 μg/ml of buffer.

79. The pharmaceutical composition of claim 78, wherein said antigen composition is present as at least about 200 μg/ml of buffer.